Last reviewed · How we verify
Bupivicaine Infusion
At a glance
| Generic name | Bupivicaine Infusion |
|---|---|
| Also known as | Marcaine |
| Sponsor | Chang, Steve S., M.D. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (PHASE4)
- Post Operative Infusion Pump Pain Study (PHASE4)
- Erector Spinae Plane (ESP) Block vs Intravenous Lignocaine Infusion in (VATS) (NA)
- Local Anesthetic as Single Shot Versus Catheter in Patients Undergoing Video Assisted Thoracoscopic Surgery (PHASE2)
- Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery (PHASE3)
- Role of Dexmedetomidine as Synergistic Agent (PHASE2, PHASE3)
- Prospective Comparative Study Between Ultrasound-guided Continuous Erector Spinae Plane Block and the Use of Intravenous Patient Controlled Analgesia for Management of Pain in Patients With Multiple Fracture Ribs (NA)
- Total Knee Replacement TIVA With Robotic Arm Assisted (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivicaine Infusion CI brief — competitive landscape report
- Bupivicaine Infusion updates RSS · CI watch RSS
- Chang, Steve S., M.D. portfolio CI